School of Communication and Information Engineering, Shanghai University, Shanghai, China.
PET Center and National Research Center for Aging and Medicine & National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Behav Neurol. 2021 Dec 30;2021:2230196. doi: 10.1155/2021/2230196. eCollection 2021.
The Parkinson's Disease Progressive Neuroimaging Initiative (PDPNI) is a longitudinal observational clinical study. In PDPNI, the clinical and imaging data of patients diagnosed with Parkinsonian syndromes and Idiopathic rapid eye movement sleep behavior disorder (RBD) were longitudinally followed every two years, aiming to identify progression biomarkers of Parkinsonian syndromes through functional imaging modalities including FDG-PET, DAT-PET imaging, ASL MRI, and fMRI, as well as the treatment conditions, clinical symptoms, and clinical assessment results of patients. From February 2012 to March 2019, 224 subjects (including 48 healthy subjects and 176 patients with confirmed PDS) have been enrolled in PDPNI. The detailed clinical information and clinical assessment scores of all subjects were collected by neurologists from Huashan Hospital, Fudan University. All subjects enrolled in PDPNI were scanned with F-FDG PET, C-CFT PET, and MRI scan sequence. All data were collected in strict accordance with standardized data collection protocols.
帕金森病进展性神经影像学倡议（PDPNI）是一项纵向观察性临床研究。在 PDPNI 中，对诊断为帕金森综合征和特发性快速眼动睡眠行为障碍（RBD）的患者的临床和影像学数据进行了每两年一次的纵向随访，旨在通过功能成像方式（包括 FDG-PET、DAT-PET 成像、ASL MRI 和 fMRI）识别帕金森综合征的进展生物标志物，以及患者的治疗情况、临床症状和临床评估结果。自 2012 年 2 月至 2019 年 3 月，224 名受试者（包括 48 名健康受试者和 176 名确诊为 PDS 的患者）已被纳入 PDPNI。华山医院的神经病学家收集了所有受试者的详细临床信息和临床评估评分。所有纳入 PDPNI 的受试者均接受了 F-FDG PET、C-CFT PET 和 MRI 扫描序列扫描。所有数据均按照严格的标准化数据采集协议进行收集。
